ProQR Therapeutics’ experimental therapy QRX-704 significantly reduced levels of the toxic huntingtin (HTT) protein clumps that fuel Huntington’s disease in a mouse model of the disease, a study showed. The therapy, an antisense oligonucleotide (ASO) designed to promote the generation of a shorter, but working version of…
I love to write, but staring at a blank screen before my fingers start to press down on the keyboard can be daunting. That’s why I appreciate my wife, Jill, collaborating with me on these columns. She’s tremendously helpful in discussing possible topics with me and making countless suggestions…
Reduced volumes of gray matter in certain regions of the brain are tied to poorer quality of life in people with Huntington’s disease, a new study reports. The study, “Brain, cognitive, and physical disability correlates of decreased quality of life in patients with Huntington’s disease,” was…
Sleep has lately been a great concern for my wife, Jill, and me. After she recently had a meltdown about realizing she’s going to die young — sadly, Jill is gene-positive for Huntington’s disease (HD) — she realized her sleep patterns were atrocious, as she’d been getting only…
Social support for children of a parent with Huntington’s disease from someone other than a caregiver is important in helping them manage stress and adversity, but there are obstacles to obtaining that support, a study has found. People who’ve lived with a parent with Huntington’s reported that, while social…
Due to possible side effects, dosing is being paused in the Phase 2 VIBRANT-HD clinical trial of oral branaplam (LMI070) in adults with Huntington’s disease. A scheduled assessment found “early signs” that “branaplam might be causing peripheral neuropathy,” a condition marked by pain or numbness in the extremities caused by damage…
Because my wife, Jill, and I live less than half an hour away from Washington, D.C., commonly listed as one of the 10 most visited cities in the United States, we like to play tourist and visit the nation’s capital on weekends as often as we can. The last time…
In my previous column, I wrote about the need for new genetic testing options for people at risk for Huntington’s disease (HD), and teased a new passion project I’ve been working on. I’m excited to share a bit more about my endeavor in hopes of helping the HD…
A Phase 2 trial of pepinemab failed to significantly improve certain cognitive abilities in people with prodromal to early Huntington’s disease, not meeting a primary study goal. But data indicated that diagnosed patients in early disease stages, those with existing cognitive and functional impairments at the study’s start, did…
Recently, a reader of this column posted a comment that touched me. It also reminded me how precarious the caregiving journey can be and how important it is to learn as much as possible about Huntington’s disease (HD). Since my wife, Jill, was diagnosed as gene-positive for HD in…
Get regular updates to your inbox.
